Found 56 clinical trials
Cessation of Long Term NAs vs. Keeping on NAs Among CHB Patients (CNAVK)
To Identify the collected cases who can stop NAs safely with satisfactory clinical outcome including sustain viral remission and HBsAg clearance among chronic hepatitis B(CHB) patients.
- 0 views
- 27 Feb, 2022
- 1 location
A Phase 2a, Open-Label Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)
treatment(s) as measured by the proportion of participants who achieve functional cure, defined as hepatitis B surface antigen (HBsAg) loss and hepatitis B virus (HBV)deoxyribonucleic acid (DNA) < lower
- 4 views
- 28 Oct, 2022
- 26 locations
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
appearance of anti-HBc and/or HBsAg) at week 48.
- 7 views
- 24 Jan, 2021
- 1 location
A Mechanistic Study of GSK3228836 With Fine Needle Aspiration (FNA) in Participants With Chronic Hepatitis B (B-Fine)
investigate the virologic and immunologic correlates of hepatitis B virus surface antigen (HBsAg) loss observed in participants when treated for 12 weeks with 300 milligrams (mg) GSK3228836. Repeat fine
- 2 views
- 07 Oct, 2022
- 5 locations
Neovac 2 Burkina Faso: Impact of the Integration of Hepatitis B Birth Dose Vaccine Into the Infant Immunization Schedule (NEOVAC2BK)
Hepatitis B virus (HBV) infection is an important global health problem, and the WHO adopted a strategy to eliminate HBV infection as a public health threat by the year 2030. In order to eliminate, it is critical to prevent the mother-to-child transmission (MTCT) of hepatitis B. Since 2009, the WHO …
- 0 views
- 30 Apr, 2022
- 2 locations
Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC
incidence, however, such risk is not completely eliminated under NA treatment. The recent availability of commercial quantitative assays of serum hepatitis B surface antigen (HBsAg) has enabled
- 1 views
- 27 Feb, 2022
- 1 location
Study on Clinical Program Optimization of Inactive Hepatitis B Surface Antigen (HBsAg) Carriers (IHCs)
A multicenter, randomized controlled trial design was used to select patients with chronic hepatitis B in the immune control phase (i.e. HBsAg positive, HBeAg negative, normal ALT and HBsAg
- 0 views
- 04 Oct, 2022
- 1 location
The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide (CLL1818)
Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive.
- 0 views
- 21 Mar, 2022
- 29 locations
Prophylactic Entecavir for HBV Reactivation in Past HBV Infected Patients With Hematopoietic Stem Cell Transplantation
This study is a randomized, prospective, comparative study of the effectiveness of prophylactic entecavir treatment for HBV reactivation in past HBV infected patients (HBsAg-, HBcIgG+) with
- 0 views
- 26 Jul, 2021
- 1 location
The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection
objectives: To explore HBsAg loss and kinetics during the study period To assess the anti-viral effect during the study period To evaluate the rate of ALT normalization
- 0 views
- 02 Oct, 2021
- 4 locations